Testing a New Chemotherapy Drug, KRT-232 (AMG 232) in Combination With Standard Chemotherapy (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Interventions: Drug: Cytarabine; Drug: Idarubicin; Drug: Idarubicin Hydrochloride; Drug: MDM2 Inhibitor AMG-232 Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Leukemia | Myelodysplastic Syndrome | Research